BIOMAT Database Logo BIOMAT Database Logo

Trivalent cold recombinant influenza live vaccine in institutionalized children with bronchial asthma and patients with psychomotor retardation. 1993

Y Tanaka, and K Ueda, and C Miyazaki, and M Nakayama, and K Kusuhara, and K Okada, and K Tokugawa, and R Shibata, and S Nishima, and N Yamane
Department of Pediatrics, Faculty of Medicine, Kyushu University, Fukuoka, Japan.

Twenty asthmatic children and 48 patients with severe psychomotor retardation were inoculated intranasally with trivalent cold-adapted recombinant (CR) influenza vaccine containing CR-125 (H1N1), CR-159 (H3N2) and CRB-117 (B). The vaccinees were mostly seropositive. Severe adverse reactions or asthmatic attacks were not observed, but 7 (15%) of 48 vaccinees with severe psychomotor retardation developed mild to moderate fever. Significant antibody responses in hemagglutination-inhibition tests were demonstrated in 33 (49%) vaccinees to CR-125, 20 (29%) to CR-159 and 8 (12%) to CRB-117. Two nosocomial outbreaks of influenza were observed in the subsequent winter. During an outbreak with H3N2 in one ward of severe psychomotor retardation patients, 2 (11%) of 18 vaccinees became infected compared with 10 (48%) of 21 placebo controls in the same ward (P < 0.05). In the other outbreak, with influenza B virus, 2 (14%) of 14 vaccinees and 13 (52%) of 25 controls in the ward for asthmatic children were infected (P < 0.05). The results indicate that trivalent CR vaccine is safe and effective against nosocomial outbreaks of influenza.

UI MeSH Term Description Entries
D007251 Influenza, Human An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia. Grippe,Human Flu,Human Influenza,Influenza in Humans,Influenza,Flu, Human,Human Influenzas,Influenza in Human,Influenzas,Influenzas, Human
D007252 Influenza Vaccines Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed and attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The flu vaccines may be mono- or multi-valent, which contains one or more ALPHAINFLUENZAVIRUS and BETAINFLUENZAVIRUS strains. Flu Vaccine,Influenzavirus Vaccine,Monovalent Influenza Vaccine,Universal Flu Vaccine,Universal Influenza Vaccine,Flu Vaccines,High-Dose Trivalent Influenza Vaccine,Influenza Vaccine,Influenza Virus Vaccine,Influenza Virus Vaccines,Influenzavirus Vaccines,Intranasal Live-Attenuated Influenza Vaccine,LAIV Vaccine,Monovalent Influenza Vaccines,Quadrivalent Influenza Vaccine,Trivalent Influenza Vaccine,Trivalent Live Attenuated Influenza Vaccine,Universal Flu Vaccines,Universal Influenza Vaccines,Flu Vaccine, Universal,High Dose Trivalent Influenza Vaccine,Influenza Vaccine, Monovalent,Influenza Vaccine, Quadrivalent,Influenza Vaccine, Trivalent,Influenza Vaccine, Universal,Intranasal Live Attenuated Influenza Vaccine,Vaccine, Flu,Vaccine, Influenza,Vaccine, Influenza Virus,Vaccine, Influenzavirus,Vaccine, LAIV,Vaccine, Monovalent Influenza,Vaccine, Quadrivalent Influenza,Vaccine, Trivalent Influenza,Virus Vaccine, Influenza
D007326 Institutionalization The caring for individuals in institutions and their adaptation to routines characteristic of the institutional environment, and/or their loss of adaptation to life outside the institution. Institutionalized Persons,Institutionalizations,Institutionalized Person,Person, Institutionalized,Persons, Institutionalized
D009975 Orthomyxoviridae A family of RNA viruses causing INFLUENZA and other respiratory diseases. Orthomyxoviridae includes INFLUENZAVIRUS A; INFLUENZAVIRUS B; INFLUENZAVIRUS C; INFLUENZAVIRUS D; ISAVIRUS; and THOGOTOVIRUS. Influenza Viruses,Myxoviruses,Orthomyxoviruses,Influenza Virus,Myxovirus,Orthomyxovirus
D011596 Psychomotor Disorders Abnormalities of motor function that are associated with organic and non-organic cognitive disorders. Psychomotor Impairment,Developmental Psychomotor Disorders,Psychomotor Disorders, Developmental,Developmental Psychomotor Disorder,Impairment, Psychomotor,Impairments, Psychomotor,Psychomotor Disorder, Developmental,Psychomotor Impairments
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003428 Cross Infection Any infection which a patient contracts in a health-care institution. Hospital Infections,Nosocomial Infections,Health Care Associated Infection,Health Care Associated Infections,Healthcare Associated Infections,Infection, Cross,Infections, Hospital,Infections, Nosocomial,Cross Infections,Healthcare Associated Infection,Hospital Infection,Infection, Healthcare Associated,Infection, Hospital,Infection, Nosocomial,Infections, Cross,Infections, Healthcare Associated,Nosocomial Infection
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

Y Tanaka, and K Ueda, and C Miyazaki, and M Nakayama, and K Kusuhara, and K Okada, and K Tokugawa, and R Shibata, and S Nishima, and N Yamane
Multidose, live attenuated, cold-recombinant, trivalent influenza vaccine in infants and young children.
May 1994, The Journal of infectious diseases,
Y Tanaka, and K Ueda, and C Miyazaki, and M Nakayama, and K Kusuhara, and K Okada, and K Tokugawa, and R Shibata, and S Nishima, and N Yamane
Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.
October 2006, The Pediatric infectious disease journal,
Y Tanaka, and K Ueda, and C Miyazaki, and M Nakayama, and K Kusuhara, and K Okada, and K Tokugawa, and R Shibata, and S Nishima, and N Yamane
Immunization of infants and young children with live attenuated trivalent cold-recombinant influenza A H1N1, H3N2, and B vaccine.
April 1992, The Journal of infectious diseases,
Y Tanaka, and K Ueda, and C Miyazaki, and M Nakayama, and K Kusuhara, and K Okada, and K Tokugawa, and R Shibata, and S Nishima, and N Yamane
Safety and efficacy of live attenuated, cold-adapted, influenza vaccine-trivalent.
November 2003, Immunology and allergy clinics of North America,
Y Tanaka, and K Ueda, and C Miyazaki, and M Nakayama, and K Kusuhara, and K Okada, and K Tokugawa, and R Shibata, and S Nishima, and N Yamane
Trivalent intranasal influenza vaccine, live.
December 2004, The Annals of pharmacotherapy,
Y Tanaka, and K Ueda, and C Miyazaki, and M Nakayama, and K Kusuhara, and K Okada, and K Tokugawa, and R Shibata, and S Nishima, and N Yamane
Safety, efficacy and effectiveness of cold-adapted, live, attenuated, trivalent, intranasal influenza vaccine in adults and children.
December 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences,
Y Tanaka, and K Ueda, and C Miyazaki, and M Nakayama, and K Kusuhara, and K Okada, and K Tokugawa, and R Shibata, and S Nishima, and N Yamane
Studies in man with a cold-recombinant live influenza B virus vaccine.
January 1982, Journal of medical virology,
Y Tanaka, and K Ueda, and C Miyazaki, and M Nakayama, and K Kusuhara, and K Okada, and K Tokugawa, and R Shibata, and S Nishima, and N Yamane
An extremely attenuated, live measles virus vaccine (CAM-EX). Persistence of low titer-antibody in institutionalized children with psychomotor retardation after vaccination.
September 1981, Biken journal,
Y Tanaka, and K Ueda, and C Miyazaki, and M Nakayama, and K Kusuhara, and K Okada, and K Tokugawa, and R Shibata, and S Nishima, and N Yamane
Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia.
July 2007, The Pediatric infectious disease journal,
Y Tanaka, and K Ueda, and C Miyazaki, and M Nakayama, and K Kusuhara, and K Okada, and K Tokugawa, and R Shibata, and S Nishima, and N Yamane
Safety of Live Attenuated Influenza Vaccine in Children With Asthma.
April 2022, Pediatrics,
Copied contents to your clipboard!